Phases précoces tumeurs solides
GO30103 (TIGIT)
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors.
Paris
EMANUELA ROMANO